NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
Reference is made to the stock exchange announcement by Lifecare ASA
("Lifecare" or the "Company") on 22 October 2025 announcing the proposed
partially underwritten rights issue of new shares in the Company (the "Rights
Issue") on the terms and conditions to be set out in an EEA prospectus (the
"Prospectus"), and to the stock exchange announcement made on 2 January 2026
announcing that the Rights Issue had been approved by an extraordinary general
meeting of the Company.
The Prospectus was approved by the Financial Supervisory Authority of Norway
on 6 January 2026. Subject to regulatory restrictions in certain
jurisdictions, the Prospectus will be made available at www.lifecare.no
(http://www.lifecare.no/), www.dnb.no/emisjoner
(https://protect.checkpoint.com/v2/r02/___http://www.dnb.no/jrnxotsjw___.YzJlOnNjaGpkdGFzOmM6bzpiYTI0ODk4N2Q4N2QyNTk4YTUyM2MzNzE4Y2Q2MDFhOTo3OjJmNjc6ZDM0Yzk3ZDA0YTUzODM2NmJkZjdiM2ZkZjFjNzM3ZDdiNDBjYjg0MTcxMjk2NGI3YjQyYTg0NjZmNDdjYmVjNDpwOkY6VA)
and www.sb1markets.no/transaksjoner/ prior to commencement of the subscription
period for the Rights Issue. The subscription period for the Rights Issue will
commence on 7 January 2026 at 09:00 hours (CET) and expire on 21 January 2026
at 16:30 hours (CET).
Important information
This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this announcement may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this
is barred or prohibited by law. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the "U.S.
Securities Act"). The securities of the Company have not been, and will not
be, registered under the U.S. Securities Act. Any sale in the United States of
the securities mentioned in this communication will be made solely to
"qualified institutional buyers" as defined in Rule 144A under the U.S.
Securities Act. No public offering of the securities will be made in the
United States.
Any offering of the securities referred to in this announcement will be made
by means of the Prospectus. This announcement is an advertisement and is not a
prospectus for the purposes of Regulation (EU) 2017/1129 of the European
Parliament and of the Council of 14 June 2017 on prospectuses to be published
when securities are offered to the public or admitted to trading on a
regulated market, and repealing Directive 2003/71/EC (as amended) as
implemented in any EEA Member State (the "Prospectus Regulation"). Investors
should not subscribe for any securities referred to in this announcement
except on the basis of information contained in the Prospectus. Copies of the
Prospectus will, following publication, be available from the Company's
registered office and, subject to certain exceptions, on the websites of DNB
Carnegie, a part of DNB Bank ASA, and SB1 Markets AS (the "Managers").
This announcement is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States, or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.
The Managers are acting for the Company in connection with the Rights Issue
and no one else and will not be responsible to anyone other than the Company
for providing the protections afforded to their respective clients or for
providing advice in relation to the Rights Issue or any transaction or
arrangement referred to in this announcement.
Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies, and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies, and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. This announcement is made by and is the responsibility of the Company.
Neither the Managers nor any of their respective affiliates make any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.
This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness, or completeness. Neither the Managers
nor any of their respective affiliates accept any liability arising from the
use of this announcement.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-01-06 10:52 CET.